How the World Trade Organization Works: Explained with Maps (History & Impact)

The TRIPS Agreement was negotiated with the expectation that it would increase innovation, technology transfer, and foreign direct investment, particularly benefiting developing countries. However, there is no empirical evidence that these promises have been fulfilled. Studies show that when intellectual property protection was strengthened in 94 developing countries over 40 years, there was no evidence that it increased innovation. Similarly, strengthening IP rights has not increased technology transfer or foreign investment. The fundamental premise that IP protection would have the same effect in developed and developing economies is flawed, as 94% of global R&D was conducted in developed countries at the time of negotiation. The existing compulsory license provisions (Articles 31 and 31bis) are insufficient to address pandemic challenges, including patent thickets, data exclusivity barriers, and failure to address know-how sharing or trade secrets. Many TRIPS flexibilities were enacted without understanding pandemic scenarios and are based on assumptions that market forces and pharmaceutical industries with IP protection will generate innovation and proper access. Article 31bis, designed to facilitate medicine access after the Doha Declaration, has proven too cumbersome—only one incident has occurred since its adoption. Other limitations include patentability criteria flexibilities that can be easily removed during bilateral or regional FTA negotiations due to power imbalances, and mechanisms that don't address technical information and biological materials claimed as commercial secrets despite public funding. Non-disclosure agreements represent a major barrier to technology transfer that cannot be addressed through existing TRIPS flexibilities. The solution is not coercion but making NDAs violations of WTO rules when connected to publicly funded research. The TRIPS Agreement was negotiated with the intention of freezing competitive advantages of developed countries vis-à-vis developing countries, not promoting public health. Ambassador Recuperator from Brazil accurately described it as intended to protect those controlling technology. Reform will require establishing a standard of review similar to anti-dumping agreements (Article 17 paragraph 6), which gives deference to member countries in determining policies. Currently, WTO panels and the Appellate Body have used strict scrutiny in interpreting TRIPS, not fully considering Articles 7 and 8 which establish policy objectives behind measures. Voluntary licenses have failed to solve technology transfer problems, and the WHO technology pool has not worked because companies are unwilling to share technologies. A TRIPS waiver would provide legal certainty for manufacturers facing infringement litigation, enabling expanded production capacity. Looking forward, the promotion of global public health will depend on regulation of private actors, and the TRIPS framework may not be the right legal framework to achieve this aim. Alternative models of R&D should put the public back at the center, with revenues continuing to be explored outside the TRIPS regime.

The Doha Declaration (2001) addresses the conflict between patent rights and public health needs by providing WTO members flexibility to issue compulsory licenses for exporting patented medicines to least developed countries and low-income nations during public health emergencies like HIV/AIDS and malaria, while encouraging technology transfer from developed to developing countries.

Compulsory licensing under WTO TRIPS Agreement allows member countries to override patent protections during emergencies (like epidemics) by compelling patent holders to license their patents to third parties at nominal government-fixed fees, provided three conditions are met: (1) reasonable public demand is not met by the patented product, (2) prices are unaffordable for the public, or (3) the patent is not being worked in that territory. Section 3D of Indian Patent Law requires therapeutic efficiency for patenting existing drugs, preventing evergreening. The Information Technology Agreement (ITA) is a plurilateral WTO agreement requiring member countries to reduce tariffs on IT products to zero, which India initially joined in 1996 but strategically avoided the second stage to protect domestic manufacturing under its 'Make in India' initiative.

The TRIPS Agreement (Trade-Related Aspects of Intellectual Property Rights) emerged as part of the WTO framework, establishing minimum IP standards worldwide. Approximately 40 countries previously without pharmaceutical patent protections were required to implement them. This coincided with European and North American firms shifting focus to trademarks (counterfeit goods, electronics) and arguing that IP protections needed strengthening. The general system of preferences was effectively used to force this bargain, creating a floor for future bilateral investment treaties and stronger enforcement mechanisms like the Anti-Counterfeiting Trade Agreement.

Intellectual property is an intangible property right granting monopoly control over creations of the mind, creating inherent trade-offs between innovation incentives and access restrictions. The TRIPS Agreement establishes a three-part framework: principles balancing creativity promotion with public health needs, non-discrimination requirements, and minimum IP protection standards. The Doha Declaration (2001) clarified that TRIPS should accommodate public health obligations during emergencies. During the HIV/AIDS crisis, South Africa implemented parallel imports and compulsory licensing despite lawsuits from 39 pharmaceutical companies. The 2022 ministerial decision clarified compulsory licensing procedures and permitted vaccine exports. However, TRIPS serves dual functions as both enabler and barrier—creating flexibilities while imposing minimum standards that developing countries must implement domestically. Effectiveness depends on national legislation, inter-ministerial coordination, and regional integration mechanisms.

Regional trade agreements (RTAs) have become substitutes for the WTO in the short run, particularly because the WTO's dispute settlement committee does not function effectively. However, in the long run, RTAs can also serve as complements to the multilateral system. Economic globalization continues because products like smartphones are still produced by many countries and sold to many countries, even though protectionism has reduced the number of countries involved in production. The three major trading blocs (USMCA, RCP, and EU) are not 100% isolated but are trying to connect through ongoing negotiations like the China-EU CAI and China-ASEAN FTA.

Approximately 60% of world trade is now covered by regional or bilateral agreements, raising questions about multilateralism's future. However, bilateral agreements are complementary to, not replacements for, the multilateral system. The WTO provides more security and eliminates discrimination, particularly benefiting poorest countries that don't profit from bilateral agreements. Regional agreements create a 'spaghetti bowl' of different rules complicating trade. The multilateral system is essential for universal rules like intellectual property standards and subsidy disciplines that cannot be achieved bilaterally.

Regional trade agreements (RTAs) and bilateral trade negotiations are not direct competitors to the WTO but serve different purposes. RTAs allow countries to negotiate new rules more easily than the 164-member WTO process, serving as testing grounds for new areas like electronic commerce and SME support. However, they require negotiators to divide their time between bilateral and multilateral work. The African Continental Free Trade Agreement represents a growing regional bloc that complements rather than competes with the WTO's multilateral framework.

Regional and bilateral trade agreements typically precede and test boundaries of trade rules before they reach multilateral levels. Successful smaller initiatives often serve as nuclei that attract additional countries and eventually incorporate disciplines into broader multilateral frameworks. Most such negotiations fail, but those that succeed have better chances at multilateral adoption, complementing rather than replacing the WTO system.

Multilateral trade refers to the broad world setting involving all countries, not just regional or group agreements. The WTO is the real multilateral body in terms of trade. Regional agreements like NAFTA or the TPP are not multilateral and must be dealt with separately.

The World Trade Organization (WTO) sets limits on agricultural subsidies, allowing developed nations up to 5% and developing nations up to 10% of production value; however, the US has challenged India at the WTO, alleging that India provides wheat subsidies exceeding these limits, paying farmers more than half the market value, which raises questions about how developing nations balance food security needs with international trade obligations.

Global agricultural trade is shaped by subsidies, disputes, and geopolitical competition. The Brazil-India sugar dispute involved WTO rulings against India's export subsidies, reducing Indian sugar exports. The Boeing-Airbus dispute between the US and EU involved accusations of subsidies, leading to retaliatory tariffs on European wine and cheese. The Australia-China trade dispute, triggered by tensions over the COVID-19 virus origins, saw China impose 80% tariffs on Australian barley, wine, and beef. Australia's heavy dependence on the Chinese market created asymmetrical vulnerability. This dispute was part of broader strategic rivalry, including Australia's alignment with US-led alliances like the Quad. The case demonstrates how agricultural trade can become a battlefield in broader geopolitical conflicts, with significant impacts on domestic producers and food security.

The Airbus-Boeing subsidy dispute at the WTO demonstrates that trade disputes are rarely clear-cut victories; both sides can claim partial success, with Airbus winning on most charges (127-128 out of 240) while Boeing retains the right to impose tariffs, illustrating how international trade disputes involve complex negotiations where the 'winner' depends on how success is measured and what future actions are permitted.

The Airbus-Boeing trade dispute originated from the EU's argument that Airbus received public subsidies, while the US argued that Boeing benefited from military contracts. The speaker explains that Airbus was created through a French-German initiative requiring significant public funding, while Boeing's military contracts (like those with McDonald's) were not considered subsidies. The dispute led to the removal of import/export tariffs on aircraft in 1980, demonstrating that trade wars benefit no one.